版本:
中国

BRIEF-Molecular Partners provides additional details on clinical studies of MP0250​

May 30 MOLECULAR PARTNERS AG:

* ‍PROVIDES ADDITIONAL DETAILS ON CLINICAL STUDIES OF PROPRIETARY LEAD ONCOLOGY ASSET MP0250​

* ‍FIRST PATIENT DOSED IN PHASE 2 MULTIPLE MYELOMA STUDY​

* ‍IND SUBMISSION TO FDA IN H2 2017 PLANNED FOR MP0250 IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER (EGFR MUT NSCLC)​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐